HYDERABAD, India–(BUSINESS WIRE)– Aragen Life Sciences (voorheen GVK BIO), een toonaangevende organisatie voor contractonderzoek en -ontwikkeling, met hoofdkantoor in Hyderabad, India, kondigt een uitbreiding aan van hun overeenkomst voor ontdekkingsonderzoek met Boehringer Ingelheim, met als doel het versnellen de ontdekkingspijplijn van Boehringer Ingelheim.

Deze voorkeurspartnerschap stelt Boehringer Ingelheim, een toonaangevend, door onderzoek gedreven farmaceutisch bedrijf, in staat om verschillende ontwerpelementen op te nemen, een breed scala aan chemotypen te synthetiseren, te profileren en vervolgens te karakteriseren tegen belangrijke doelen die van belang zijn in snelle optimalisatiecycli. Het partnerschap maakt ook de geïntegreerde opschaling van verbindingen mogelijk voor grotere preklinische studies. Biologische screening van geschikte chemische groepen om de besluitvorming met snelheid en nauwkeurigheid te stimuleren, is ook opgenomen in het partnerschap. Aragen zal een aanzienlijk deel van zijn campus in Hyderabad wijden om deze alliantie te ondersteunen.

Aragen Announces Expansion of Discovery Research Agreement with Boehringer Ingelheim

HYDERABAD, India–(BUSINESS WIRE)– Aragen Life Sciences (formerly GVK BIO), a leading Contract Research and Development Organization, headquartered out of Hyderabad, India, announces an expansion of their discovery research agreement with Boehringer Ingelheim, with the goal of accelerating the discovery pipeline of Boehringer Ingelheim.

This preferred partnership allows Boehringer Ingelheim, a leading research driven pharmaceutical company, to incorporate several design elements, synthesize, profile, and then characterize a wide range of chemotypes against key targets of interest in swift optimization cycles. The partnership also allows for the integrated up-scaling of compounds for larger pre-clinical studies. Biology screening of appropriate chemical moieties to drive decision making with speed and accuracy is also included in the partnership. Aragen will dedicate a sizeable portion of its campus in Hyderabad to support this alliance.

“We at Aragen believe that ‘In Every Molecule is the Possibility for Better Health’, and are excited about the opportunity to expand our partnership with Boehringer Ingelheim, a global leader in the discovery and development of novel medicines. It has been our privilege to collaborate with the scientists at Boehringer Ingelheim, and we thank them for their trust and confidence in the Aragen team. Together, we look forward to advancing Boehringer Ingelheim’s innovative approaches into successful clinical outcomes that can have the potential to ultimately benefit patients,” said Manni Kantipudi, CEO at Aragen.

About Aragen

Aragen Life Sciences Pvt Ltd (“Aragen”) is a global leader in providing discovery, development and manufacturing solutions for life sciences firms. With a team of over 3100 professionals, and through a network of sites around the world, we offer a seamless, integrated platform to advance customer programs from discovery through commercialization for both small molecules and biologics. Established in 2001, Aragen now serves over 450 customers worldwide across multiple modalities and therapeutic areas. For more information, visit www.aragen.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005162/en/

Contacts

Aragen Life Sciences: Sarat Patanaik, +91 95732 80064, sarat.patanaik@aragen.com
MediaMedic Communications Pvt.Ltd.: Bhavna Pathak, +918830654608, info@mediamedichealth.com